Voluntary Delisting: Summary & Explanation
Botanical Psilocybin & Alcohol Use Disorder: A Promising Treatment
Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder
